Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Aliskiren reduces albuminuria after kidney transplantation.

Tylicki L, Debska-Slizien AM, Lizakowski S, Przybylska M, Heleniak Z, Renke M, Chamienia AL, Biedunkiewicz B, Rutkowski P, Małgorzewicz S, Rutkowski B.

Acta Biochim Pol. 2017;64(2):221-226. doi: 10.18388/abp.2016_1297. Epub 2017 Apr 28.

2.

Nonsteroidal anti-inflammatory drug use in patients with chronic kidney disease.

Heleniak Z, Cieplińska M, Szychliński T, Rychter D, Jagodzińska K, Kłos A, Kuźmiuk I, Tylicka MJ, Tylicki L, Rutkowski B, Dębska-Ślizień A.

J Nephrol. 2016 Sep 27. [Epub ahead of print]

PMID:
27679400
3.

Gastrointestinal Pathologies in Patients After Successful Renal Transplantation-A Pilot Study.

Dobies A, Renke M, Wołyniec W, Palenicek L, Januszczyk J, Król E, Lizakowski S, Rutkowski P, Tylicki L, Dębska-Ślizień A, Rutkowski B.

Transplant Proc. 2016 Jun;48(5):1566-9. doi: 10.1016/j.transproceed.2016.02.060.

PMID:
27496448
4.

Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails.

Rutkowski B, Tylicki L.

J Ren Nutr. 2015 Mar;25(2):194-200. doi: 10.1053/j.jrn.2014.10.026. Epub 2015 Jan 6. Review.

PMID:
25576239
5.

Treatment of hypertension in chronic kidney disease patients under specialized care: one-center cross-sectional analyses.

Tylicki L, Jakubowska A, Lizakowski S, Zakrzewska A, Weber E, Świetlik D, Rutkowski B.

Blood Press. 2015 Apr;24(2):79-85. doi: 10.3109/08037051.2014.986931. Epub 2014 Dec 26.

PMID:
25541646
6.

Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.

Tylicki L, Jakubowska A, Lizakowski S, Świetlik D, Rutkowski B.

J Renin Angiotensin Aldosterone Syst. 2015 Mar;16(1):145-52. doi: 10.1177/1470320314550018. Epub 2014 Oct 16.

PMID:
25324423
7.

Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-Placebo controlled, randomized, cross-over study.

Renke M, Lizakowski S, Tylicki L, Rutkowski P, Knap N, Heleniak Z, Sławińska-Morawska M, Aleksandrowicz-Wrona E, Januszczyk J, Wójcik-Stasiak M, Małgorzewicz S, Woźniak M, Rutkowski B.

Adv Med Sci. 2014 Sep;59(2):256-60. doi: 10.1016/j.advms.2014.03.003. Epub 2014 Jun 10.

PMID:
25105662
8.

Dual blockade of the renin-angiotensin-aldosterone system in renal disease: what is the future? Authors' reply.

Lizakowski S, Tylicki L, Rutkowski P, Rutkowski B.

Pol Arch Med Wewn. 2014;124(1-2):73-4. No abstract available.

9.

Direct renin inhibition--a promising strategy for renal protection?

Lizakowski S, Tylicki L, Rutkowski B.

Med Sci Monit. 2013 Jun 12;19:451-7. doi: 10.12659/MSM.883949. Review.

10.

Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease.

Lizakowski S, Tylicki L, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J, Rutkowski B.

Pol Arch Med Wewn. 2013;123(5):221-7. Epub 2013 Apr 25.

11.

[Isoprostanes - important marker of the oxidative stress estimation in patients with chronic kidney disease].

Renke M, Knap N, Tylicki L, Rutkowski P, Lizakowski S, Woźniak M, Rutkowski B.

Pol Merkur Lekarski. 2013 Jan;34(199):14-7. Polish.

PMID:
23488278
12.

Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.

Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Sławińska-Morawska M, Aleksandrowicz E, Łysiak-Szydłowska W, Rutkowski B.

Int Urol Nephrol. 2012 Dec;44(6):1763-70.

13.

The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?.

Tylicki L, Lizakowski S, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J, Rutkowski B.

Kidney Blood Press Res. 2012;36(1):335-43. doi: 10.1159/000343391. Epub 2012 Dec 12.

14.

Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.

Tylicki L, Lizakowski S, Rutkowski B.

J Nephrol. 2012 Nov-Dec;25(6):900-10. doi: 10.5301/jn.5000134. Review.

PMID:
22684647
15.

Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease.

Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Sławińska-Morawska M, Aleksandrowicz-Wrona E, Małgorzewicz S, Rutkowski B.

Am J Hypertens. 2012 Jun;25(6):636-9. doi: 10.1038/ajh.2012.14. Epub 2012 Feb 23.

PMID:
22357413
16.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators.

Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.

17.

Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.

Renke M, Tylicki L, Rutkowski P, Neuwelt A, Larczyński W, Ziętkiewicz M, Aleksandrowicz E, Lysiak-Szydłowska W, Rutkowski B.

Acta Biochim Pol. 2010;57(4):547-52. Epub 2010 Nov 16.

18.

The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: a placebo-controlled, randomized, cross-over study.

Renke M, Tylicki L, Rutkowski P, Larczynski W, Neuwelt A, Aleksandrowicz E, Łysiak-Szydłowska W, Rutkowski B.

Med Sci Monit. 2010 Jul;16(7):PI13-8.

PMID:
20581787
19.

Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.

Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Łysiak-Szydłowska W, Woźniak M, Rutkowski B.

Acta Biochim Pol. 2010;57(1):119-23. Epub 2010 Mar 22.

20.

Combination treatment and renal function in patients with chronic kidney disease.

Renke M, Rutkowski P, Tylicki L, Rutkowski B.

J Renin Angiotensin Aldosterone Syst. 2010 Jun;11(2):146-7. doi: 10.1177/1470320310364274. Epub 2010 Mar 11. No abstract available.

PMID:
20223790

Supplemental Content

Loading ...
Support Center